RxDoctor Payments Data

Francis Rossi

Podiatrist · Jersey City, NJNPI 1487710851

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,378 of the $6,926 with a category attached, or 77.7%. Integra Lifesciences Corporation accounts for 81.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $5,564, more than ten times the $27 reported in 2019. Among podiatrist clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,926in general payments, 2019–2025

Across 41 payments — averaging $168.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$6K
  • Musculoskeletal Transplant Foundation Inc.$456
  • Lifenet Health$279
  • Stryker$140
  • Smith+Nephew$125
  • Cardiovascular Systems Inc.$93
  • plus $166 from 5 others

What the payments were for

  • Food & beverage$1,52822%
  • Gifts$190%
  • Other$5,37878%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,926 in reported general payments places this provider in the 90th percentile of 382 podiatrist providers in New Jersey.

See all podiatrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$807,514
Medicare patients
347
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.15$49,471
Ammonium Lactate143$2,436
Ketoconazole58$1,538
Colchicine11$1,343
Mupirocin127$986
Clotrimazole23$968
Diclofenac Sodium37$768
Ciclopirox18$630
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip34$620
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav61$553
Mometasone Furoate21$361
Gabapentin56$350
Ciprofloxacin Hcl36$327
Doxycycline Hyclate40$320
CiclopiroxCiclopirox Olamine12$265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$125$49,47115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 podiatrist providers in New Jersey.

Other podiatrist in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →